Korro reports preclinical data for KRRO-111 in alpha-1 antitrypsin deficiency
Korro Bio announced preclinical results for KRRO-111, its development candidate for alpha-1 antitrypsin deficiency (AATD), in an October 22, 2026 press release filed as Exhibit 99.1. The company says the studies, which were conducted in mice and human liver cells, show RNA editing and reduced toxic Z-AAT protein, and it expects a regulatory submission in the first half of 2027. The filing reports no financial results, and the data are preclinical, so they do not show how the drug will perform in people.
Key points
- In repeat-dose mouse studies, SERPINA1 mRNA editing reached 96% and total AAT concentrations were about 6-fold versus vehicle at Day 57.
- Whole liver Z-AAT levels fell 95% relative to vehicle control in immunocompetent C57BL/6-PiZ mice at Day 57.
- Korro expects to submit a regulatory filing for KRRO-111 in the first half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.